Corporate Information

8229 Boone Boulevard
Suite 802
Vienna, VA 22182

Phone: (703) 506-9460
Fax: (703) 506-9471
www.cel-sci.com

Recent News Releases

CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

Friday, May 18, 2012

InPlay: CEL-SCI Corp releases letter to shareholders; says 'executing our Phase III clinical trial to the highest standard'

Friday, May 18, 2012

CEL-SCI Corporation Releases Letter to Shareholders

Friday, May 18, 2012

[Business Wire] - The following letter was provided to shareholders by CEL-SCI Corporation for today’s annual shareholder meeting:

Follow Me

CEL-SCI Corporation

Corporate Snapshot

CEL-SCI Corp. ("CEL-SCI" or "the Company") develops cancer and infectious disease products that empower immune system defenses. CEL-SCI's lead product candidate is Multikine®, a non-toxic, second-generation cancer immunotherapy. The immunotherapy field recently gained momentum with the launch of Dendreon Corp.'s (DNDN-NASDAQ) Provenge®, which in April 2010 became the first FDA-approved therapeutic cancer vaccine. Provenge®, a treatment for prostate cancer, validated the possibility of harnessing the human immune system against a patient's own cancer. CEL-SCI's Multikine® immunotherapy, designated as an Orphan Drug by the FDA, is poised to enter a global Phase III trial in the second half of 2010 for advanced primary head and neck cancer. Multikine® has several novel characteristics that may differentiate it from the present generation of cancer vaccines: (1) in contrast to many autologous approaches, which must be made specific to each patient, Multikine® can be used off-the-shelf, thus large-scale manufacturing is possible; (2) Multikine® offers both active and passive immunity, indicating that no outside antigen is needed; and (3) Multikine® is administered to patients when the immune system is strongest (before surgery, radiation, or chemotherapy), which CEL-SCI has found to be an optimal time for inducing an effective anti-tumor immune response. Multikine® has been shown to kill ~50% of tumor cells before standard treatments commence. As well, it renders residual cancer cells that survive treatment more susceptible to radiation and chemotherapy.